Skip to main content

Table 1 Summary of the baseline characteristics of the patients

From: A phase III, randomized, two-armed, double-blind, parallel, active controlled, and non-inferiority clinical trial to compare efficacy and safety of biosimilar adalimumab (CinnoRA®) to the reference product (Humira®) in patients with active rheumatoid arthritis

Variable CinnoRA® Humira® P value
Age 48.29 ± 12.72 47.59 ± 11.48 0.73
Sex, n (%)
 Male 10 (14.71%) 8 (11.76%) 0.85*
 Female 58 (85.29%) 60 (88.24%)
Swollen joint count, 28 joints 9.96 ± 7.39 9.46 ± 6.98 0.69
Tender joint count, 28 joints 9.46 ± 8.23 9.66 ± 7.97 0.88
Patient assessment of pain 67.21 ± 23.51 70.22 ± 21.93 0.44
Patient global assessment of disease activity 70.15 ± 20.35 70.74 ± 22.21 0.87
Physician’s global assessment of disease activity 68.97 ± 17.38 70.44 ± 17.68 0.63
CRP (mg/L) 21.40 ± 25.98 18.90 ± 23.90 0.57
ESR (mm/h) 32.65 ± 21.24 31.12 ± 24.01 0.69
HAQ 1.25 (1.38) 1.38 (1.13) 0.56
DAS28-ESR 5.51 ± 1.24 5.47 ± 1.28 0.87
RF 63.76 ± 57.22 76.95 ± 65.66 0.22
  1. Data are shown as mean ± SD and were analyzed using the independent t test unless stated otherwise. CRP C-reactive protein, DAS28 disease activity score in 28 joints, ESR erythrocyte sedimentation rate, HAQ health assessment questionnaire, RF rheumatoid factor. *Data were analyzed using Pearson's chi-squared test. Scores are shown as median (interquartile range) and were analyzed using the Mann-Whitney U test